RUCONEST® (conestat alfa)
This product has been approved for use by the European Medicines Agency (EMA) in Europe, the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom and the Food and Drug Administration (FDA) in the United States.
Available product information:
REPORT AN ADVERSE EVENT
For Pharming as a global biopharmaceutical company, ensuring patient safety is our number one goal, beyond mere compliance with worldwide regulations. By reporting adverse events for Pharming medicinal products, you help us to ensure the safety of our products. Your information will also enable Pharming to fulfill its reporting requirements to Health Authorities, which requires that Pharming provides information on adverse events with our products.
In case you experience or suspect any adverse event following the administration of our product(s), please contact Pharming.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.